421 related articles for article (PubMed ID: 25681059)
21. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
van der Heijde D; Baraliakos X; Gensler LS; Maksymowych WP; Tseluyko V; Nadashkevich O; Abi-Saab W; Tasset C; Meuleners L; Besuyen R; Hendrikx T; Mozaffarian N; Liu K; Greer JM; Deodhar A; Landewé R
Lancet; 2018 Dec; 392(10162):2378-2387. PubMed ID: 30360970
[TBL] [Abstract][Full Text] [Related]
22. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases.
Van Rompaey L; Galien R; van der Aar EM; Clement-Lacroix P; Nelles L; Smets B; Lepescheux L; Christophe T; Conrath K; Vandeghinste N; Vayssiere B; De Vos S; Fletcher S; Brys R; van 't Klooster G; Feyen JH; Menet C
J Immunol; 2013 Oct; 191(7):3568-77. PubMed ID: 24006460
[TBL] [Abstract][Full Text] [Related]
23. Exposure-response relationships for the efficacy and safety of filgotinib and its metabolite GS-829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies.
Meng A; Anderson K; Nelson C; Ni L; Chuang SM; Bellanti F; Chang P; Comisar C; Kearney BP; Bartok B; Mathias A
Br J Clin Pharmacol; 2022 Jul; 88(7):3211-3221. PubMed ID: 35072287
[TBL] [Abstract][Full Text] [Related]
24. Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights.
Raimondo MG; Biggioggero M; Coletto LA; Ramming A; Caporali R; Favalli EG
Expert Rev Clin Pharmacol; 2021 Jun; 14(6):661-670. PubMed ID: 33847204
[TBL] [Abstract][Full Text] [Related]
25. Dose/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis.
Zhang X; Chua L; Ernest C; Macias W; Rooney T; Tham LS
CPT Pharmacometrics Syst Pharmacol; 2017 Dec; 6(12):804-813. PubMed ID: 28891251
[TBL] [Abstract][Full Text] [Related]
26. Validated LC-MS/MS method for quantitation of a selective JAK1 inhibitor, filgotinib in rat plasma, and its application to a pharmacokinetic study in rats.
Dixit A; Kiran V; Gabani BB; Mohd Z; Trivedi RK; Mullangi R
Biomed Chromatogr; 2020 Apr; 34(4):e4802. PubMed ID: 31998982
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA).
Maringwa J; Kågedal M; Hamrén UW; Martin P; Cox E; Hamrén B
J Clin Pharmacol; 2015 Mar; 55(3):328-35. PubMed ID: 25280085
[TBL] [Abstract][Full Text] [Related]
28. Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials.
Tanaka Y; Kavanaugh A; Wicklund J; McInnes IB
Mod Rheumatol; 2022 Jan; 32(1):1-11. PubMed ID: 33740386
[TBL] [Abstract][Full Text] [Related]
29. Filgotinib in rheumatoid arthritis.
Westhovens R
Expert Rev Clin Immunol; 2023 Feb; 19(2):135-144. PubMed ID: 36396615
[TBL] [Abstract][Full Text] [Related]
30. Filgotinib as rheumatoid arthritis therapy.
Becciolini A; Di Donato E; Santilli D; Lucchini G; Mozzani F; Riva M; Ariani A
Drugs Today (Barc); 2021 Sep; 57(9):543-550. PubMed ID: 34586102
[TBL] [Abstract][Full Text] [Related]
31. Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.
Menet CJ; Fletcher SR; Van Lommen G; Geney R; Blanc J; Smits K; Jouannigot N; Deprez P; van der Aar EM; Clement-Lacroix P; Lepescheux L; Galien R; Vayssiere B; Nelles L; Christophe T; Brys R; Uhring M; Ciesielski F; Van Rompaey L
J Med Chem; 2014 Nov; 57(22):9323-42. PubMed ID: 25369270
[TBL] [Abstract][Full Text] [Related]
32. Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis.
Avci AB; Feist E; Burmester GR
Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii11-ii16. PubMed ID: 33950228
[TBL] [Abstract][Full Text] [Related]
33. Evaluating filgotinib for the treatment of rheumatoid arthritis.
Richez C; Truchetet ME
Expert Opin Pharmacother; 2021 Dec; 22(18):2435-2444. PubMed ID: 34402699
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2).
Takeuchi T; Matsubara T; Atsumi T; Amano K; Ishiguro N; Sugiyama E; Yamaoka K; Genovese MC; Kalunian K; Walker D; Gottenberg JE; de Vlam K; Bartok B; Pechonkina A; Kondo A; Gao J; Guo Y; Tasset C; Sundy JS; Tanaka Y
Mod Rheumatol; 2022 Jan; 32(1):59-67. PubMed ID: 33274687
[TBL] [Abstract][Full Text] [Related]
35. Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis.
Mysler E; Lizarraga A
Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii17-ii23. PubMed ID: 33950225
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended-Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials.
Mohamed MF; Zeng J; Marroum PJ; Song IH; Othman AA
Clin Pharmacol Drug Dev; 2019 Feb; 8(2):208-216. PubMed ID: 29688617
[TBL] [Abstract][Full Text] [Related]
37. Filgotinib, a JAK1 Inhibitor, for Treatment-Resistant Rheumatoid Arthritis.
Singh JA
JAMA; 2019 Jul; 322(4):309-311. PubMed ID: 31334773
[No Abstract] [Full Text] [Related]
38. Selective JAK inhibitors in development for rheumatoid arthritis.
Norman P
Expert Opin Investig Drugs; 2014 Aug; 23(8):1067-77. PubMed ID: 24818516
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
40. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
Boyle DL; Soma K; Hodge J; Kavanaugh A; Mandel D; Mease P; Shurmur R; Singhal AK; Wei N; Rosengren S; Kaplan I; Krishnaswami S; Luo Z; Bradley J; Firestein GS
Ann Rheum Dis; 2015 Jun; 74(6):1311-6. PubMed ID: 25398374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
